One Kendall Square, Suite B3301Cambridge, MA 02139
Brian J. G. Pereira, M.D.
President and Chief Executive Officer
Visterra discovers and develops novel antibodies for the prevention and treatment of infectious and other major diseases. The company’s proprietary antibody discovery platform generates unique structural information that identifies novel target epitopes (sites recognized by antibodies) and guides the design of antibodies which specifically target these epitopes to effectively combat disease. The company’s lead antibody product candidate, VIS410, is a broad spectrum monoclonal antibody for the prevention and treatment of both seasonal and pandemic influenza. The company is building a proprietary pipeline of novel antibodies in infectious disease, and continuing to expand its disease area focus through strategic partnerships in infectious and other diseases. Visterra was founded based on the scientific work of Dr. Ram Sasisekharan at MIT. Ed Kania is on the Board of Directors.